You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

Details for Patent: 10,124,014


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,124,014 protect, and when does it expire?

Patent 10,124,014 protects NUZYRA and is included in two NDAs.

This patent has eleven patent family members in eleven countries.

Summary for Patent: 10,124,014
Title:Minocycline compounds and methods of use thereof
Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
Inventor(s): Johnston; Sean M. (Doylestown, PA), Arbeit; Robert D. (W. Newton, MA), Bigger; Thomas J. (Norwell, MA), Molnar; Dennis P. (Hopkinton, MA), Tanaka; S. Ken (Needham, MA)
Assignee: Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:15/637,144
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;
Patent landscape, scope, and claims:

United States Patent 10,124,014: A Detailed Analysis of Scope and Claims

Overview of the Patent

United States Patent 10,124,014, titled "Minocycline compounds and methods of use thereof," pertains to the use of tetracycline compounds, specifically minocycline, for treating bacterial infections. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background of Minocycline

Minocycline is a semi-synthetic derivative of tetracycline, known for its broad-spectrum antibacterial activity. It is commonly used to treat various bacterial infections, including those caused by Gram-positive and Gram-negative bacteria[1].

Scope of the Patent

The patent scope is a critical aspect of any patent, as it defines the boundaries of what is protected by the patent.

Claim Language and Metrics

The scope of US Patent 10,124,014 can be analyzed using metrics such as independent claim length and independent claim count. These metrics are often used to measure patent scope and have been validated as having explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes[3].

Independent Claims

The patent includes several independent claims that outline the specific compositions and methods of using minocycline compounds. For instance, one embodiment describes the use of a tetracycline compound, specifically minocycline, for treating bacterial infections. These claims are detailed and specific, indicating a focused scope aimed at protecting the particular application of minocycline in this context.

Claims Analysis

Composition Claims

The patent includes claims related to the composition of minocycline compounds. These claims specify the chemical structure and formulation of the compounds, ensuring that any variations or modifications that fall within the described parameters are covered under the patent[1].

Method Claims

Method claims are another crucial aspect, detailing the procedures for using minocycline to treat bacterial infections. These claims outline the dosage, administration routes, and treatment protocols, providing a comprehensive protection for the therapeutic use of minocycline.

Dependent Claims

Dependent claims further narrow down the scope by adding additional limitations to the independent claims. These claims help in defining the patent's boundaries more precisely, ensuring that the protection is not overly broad but still encompasses the innovative aspects of the invention.

Patent Landscape

Prior Art and Novelty

The patent landscape for minocycline compounds involves a thorough review of prior art to establish novelty. The patent application would have been scrutinized to ensure that the claimed compositions and methods are new and non-obvious over existing prior art. This process is crucial in maintaining the integrity of the patent system and ensuring that only genuine innovations are protected[4].

Global Patent System

The global patent system plays a significant role in the landscape of US Patent 10,124,014. Tools like the Global Dossier and Common Citation Document (CCD) facilitate the integration of patent information across different jurisdictions, helping to identify related applications and prior art cited by various patent offices. This harmonization aids in ensuring that the patent is consistent with international standards and reduces the likelihood of overlapping or conflicting patents[4].

Post-Grant Proceedings

Patent Trial and Appeal Board (PTAB)

The Patent Trial and Appeal Board (PTAB) is a significant entity in the post-grant landscape of US patents. PTAB can review the validity of granted patents through inter partes review (IPR) and post-grant review (PGR) proceedings. These proceedings allow any person to challenge the patent's validity, which can impact the scope and claims of the patent if successful. The PTAB process is generally faster and less expensive than judicial proceedings, making it a common route for challenging patent validity[5].

Economic and Legal Implications

Patent Quality and Innovation

The quality of patents, including their scope and claims, is a subject of ongoing debate. The creation of PTAB and the introduction of IPR and PGR proceedings aim to improve patent quality by providing a more efficient system for challenging patents that should not have been granted. However, critics argue that these processes can create uncertainty and discourage investment in innovation[5].

Litigation and Licensing

The scope and claims of US Patent 10,124,014 can significantly impact litigation and licensing strategies. A well-defined scope ensures that the patent holder has clear rights, which can be enforced effectively. Conversely, overly broad or vague claims can lead to increased litigation costs and licensing complexities.

Key Takeaways

  • Specific Claims: The patent includes specific claims related to the composition and method of using minocycline compounds, ensuring a focused scope.
  • Global Integration: The global patent system, through tools like Global Dossier and CCD, helps in maintaining consistency and reducing conflicts.
  • Post-Grant Proceedings: PTAB proceedings can impact the validity and scope of the patent, offering a faster and less expensive alternative to judicial reviews.
  • Economic Implications: The patent's scope and claims have significant economic implications, affecting innovation, litigation, and licensing.

FAQs

What is the primary focus of US Patent 10,124,014?

The primary focus of US Patent 10,124,014 is the use of minocycline compounds for treating bacterial infections.

How is the scope of the patent measured?

The scope of the patent can be measured using metrics such as independent claim length and independent claim count.

What role does PTAB play in the post-grant landscape?

PTAB reviews the validity of granted patents through IPR and PGR proceedings, providing a faster and less expensive alternative to judicial reviews.

How does the global patent system impact this patent?

The global patent system, through tools like Global Dossier and CCD, ensures consistency and reduces conflicts by integrating patent information across different jurisdictions.

What are the economic implications of the patent's scope and claims?

The patent's scope and claims can impact innovation, litigation costs, and licensing strategies, influencing the overall economic viability of the invention.

Sources

  1. US10124014B2 - Minocycline compounds and methods of use thereof - Google Patents
  2. Patent Claims Research Dataset - USPTO
  3. Patent Claims and Patent Scope - SSRN
  4. Search for patents - USPTO
  5. The Patent Trial and Appeal Board and Inter Partes Review - Congressional Research Service

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,124,014

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes 10,124,014 ⤷  Try for Free TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION ⤷  Try for Free
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes 10,124,014 ⤷  Try for Free TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,124,014

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009220171 ⤷  Try for Free
Brazil PI0908951 ⤷  Try for Free
Canada 2717703 ⤷  Try for Free
Chile 2010000188 ⤷  Try for Free
China 102015602 ⤷  Try for Free
European Patent Office 2262754 ⤷  Try for Free
Japan 2011513404 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.